Tru2u.health Expands Digital Health Platform with the Addition of NAD+ - The Cellular Energy Molecule Transforming Modern Wellness

Rhea-AI Summary

Functional Brands (NASDAQ: MEHA) expanded its digital health platform Tru2u.health on April 29, 2026 by adding clinically supervised NAD+ therapy.

The platform now combines NAD+ with peptide protocols, GLP-1 weight management, board-certified telehealth, and clean supplements, and is onboarding patients nationwide subject to state telehealth rules.

News Market Reaction – MEHA

-10.52%

9 alerts

-10.52% Session close to close

-24.5% Trough in 2 hr 7 min

$2.15M Market Cap

0.4x Rel. Volume

In the Apr 29 session, MEHA declined 10.52%, reflecting a significant negative market reaction. Argus tracked a trough of -24.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.5% in the session following this news. A negative reaction despite an expanded...

Analysis

The stock dropped -10.5% in the session following this news. A negative reaction despite an expanded Tru2u.health offering would fit a pattern where structurally driven concerns overshadow product news. Recent filings referenced going-concern uncertainty, reverse split authorization ranges, and layered preferred and secured debt structures. In that context, even clinically framed additions like NAD+ therapy might not offset balance-sheet and listing risks, and weakness could reflect continued skepticism about long-term capitalization rather than the specifics of today’s launch.

Key Figures

NAD+ decline with age: 40-50% Platform pillars: 5 pillars

2 metrics

NAD+ decline with age 40-50% Research-cited drop in NAD+ levels between youth and midlife

Platform pillars 5 pillars Number of core pillars on the Tru2u.health digital health platform

Historical Context

5 past events · Latest: Apr 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 22	Tech partnership	Positive	+7.2%	AI partner-marketing deal to improve Tru2u.health customer acquisition metrics.
Apr 17	Product launch	Positive	-4.1%	Launch of non-prescription Kirkman weight loss support bundle targeting metabolism.
Mar 30	Earnings report	Neutral	-3.3%	Q4 and full-year 2025 results with modest revenue growth and margin compression.
Mar 20	Distribution expansion	Positive	+0.8%	Global iHerb distribution for P2i prenatal multivitamin to broaden reach.
Mar 16	Conference participation	Neutral	-7.8%	Planned meetings and presentations at the 38th Annual ROTH Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions mostly aligned with the tone of announcements, with one notable divergence on product-launch news.

Recent Company History

Over the last few months, Functional Brands has reported a profitability turnaround, expanded distribution for its Kirkman products, advanced Tru2u.health, and formed an AI-driven marketing partnership. Stock reactions to earnings, conferences, and product news have generally been modest, with both positive and negative moves under 10%. Against this backdrop, today’s Tru2u.health NAD+ expansion continues the shift toward a more digitally focused, clinically guided wellness platform.

Key Terms

nad+, nicotinamide adenine dinucleotide, glp-1, parp, +4 more

8 terms

nad+ medical

"with the addition of NAD+ (Nicotinamide Adenine Dinucleotide) therapy."

NAD+ is a naturally occurring molecule that helps cells turn food into usable energy and repair damage, acting like a battery and maintenance signal inside every cell. It matters to investors because drugs, supplements, or diagnostics that raise or measure NAD+ levels are a growing area of medical and consumer interest, with potential revenue, regulatory scrutiny, and clinical risk tied to claims about aging, metabolism, and disease treatment.

nicotinamide adenine dinucleotide medical

"NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme"

Nicotinamide adenine dinucleotide (NAD) is a small molecule that cells use to move energy and chemical signals around, acting like a shuttle or rechargeable battery that helps power metabolism, repair damage, and control how cells respond to stress. Investors care because therapies, diagnostics, or consumer products that change NAD levels can affect disease treatment, aging-related markets, and company valuations, making research results, regulatory news, or product claims material to financial prospects.

glp-1 medical

"includes peptide protocols, GLP-1-based weight management, and board-certified"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

parp medical

"NAD+ fuels PARP (poly-ADP-ribose polymerase) enzymes, which detect and repair"

PARP is a family of enzymes that help cells detect and repair damaged DNA; think of them as cellular repair crew members that patch small breaks. It matters to investors because medicines called PARP inhibitors can block these enzymes to kill cancer cells or make other treatments work better, so clinical trials, approvals, or setbacks for PARP-targeting drugs can strongly affect the value of companies developing them.

poly-adp-ribose polymerase medical

"NAD+ fuels PARP (poly-ADP-ribose polymerase) enzymes, which detect and repair"

Poly-ADP-ribose polymerase (PARP) is a family of enzymes that detect and help repair damaged DNA, acting like a cellular repair crew that tags breaks so other proteins can fix them. PARP matters to investors because drugs that block PARP can stop cancer cells from repairing themselves, making PARP inhibitors an important class of therapies and clinical-test targets that can drive trial results, regulatory outcomes and commercial value.

sirtuins medical

"NAD+ is required to activate sirtuins, a family of proteins described by"

Sirtuins are a family of naturally occurring proteins that act like tiny cellular switches, helping control metabolism, stress responses and processes linked to aging and cell repair. Investors watch them because drugs or tests that target sirtuins can change the value of biotechs and pharma firms — they’re potential pathways to new treatments, diagnostic tools, or biomarkers that can drive regulatory approval, sales and company valuations.

atp medical

"driving the production of ATP, the body's primary energy currency."

Adenosine triphosphate (ATP) is the primary energy carrier that cells use to power biological functions; think of it as the battery or wallet cells tap to run processes like movement, growth and chemical reactions. For investors, ATP is important because many drugs, diagnostics and laboratory tests affect or measure cellular energy — so ATP-related data can signal how a therapy works, indicate biomarker activity, or influence the commercial potential of biotech products.

telehealth technical

"GLP-1-based weight management, and board-certified telehealth support."

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Lake Oswego, Oregon--(Newsfile Corp. - April 29, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced a significant expansion of its digital health platform, www.Tru2u.health, with the addition of NAD+ (Nicotinamide Adenine Dinucleotide) therapy. This milestone enhances Tru2u.health's already comprehensive suite of solutions that includes peptide protocols, GLP-1-based weight management, and board-certified telehealth support.

"The launch of NAD+ therapy on Tru2u.health is a natural evolution of our commitment to delivering the most impactful, science-backed wellness solutions available," said Eric Gripentrog, Chief Executive Officer of Functional Brands Inc. "NAD+ sits at the foundation of how our cells produce energy and repair themselves. By making it accessible through our clinically guided platform, we're giving our patients a powerful new tool to optimize their health at the cellular level - and reinforcing Tru2u.health as the destination for comprehensive, medication-based wellness care."

What Is NAD+? The Science Behind the Molecule

NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in every living cell. It is essential to life - playing a central role in energy metabolism, DNA repair, and the activation of proteins that regulate cellular health and longevity. Without adequate NAD+, cells cannot efficiently generate the energy needed to perform their core functions. [1]

Research has identified NAD+ as one of the most important molecules in human biology, with declining NAD+ levels linked to the hallmarks of aging, metabolic dysfunction, and diminished physical and cognitive performance. [1,2] Key functions of NAD+ include:

• Cellular Energy Production - NAD+ is a critical cofactor in mitochondrial function, driving the production of ATP, the body's primary energy currency. Higher NAD+ levels are associated with greater endurance, vitality, and metabolic efficiency. [1]
• DNA Repair & Genome Stability - NAD+ fuels PARP (poly-ADP-ribose polymerase) enzymes, which detect and repair DNA damage caused by oxidative stress, UV radiation, and normal aging. Robust NAD+ availability helps maintain genomic integrity over time. [3]
• Sirtuin Activation - NAD+ is required to activate sirtuins, a family of proteins described by researchers at MIT and Harvard as central "longevity regulators." Sirtuins govern inflammation response, fat metabolism, stress resistance, and circadian rhythm regulation. [2,4]
• Neuroprotection & Cognitive Function - The brain is among the most metabolically demanding organs in the body. Peer-reviewed research has identified increasing NAD+ levels as a promising strategy for preserving cognitive ability and protecting against age-related neurological decline. [5,6]
• Muscle Recovery & Physical Performance - By supporting mitochondrial efficiency and reducing oxidative stress in muscle tissue, NAD+ can aid post-exercise recovery and sustained physical output. [1]
• Metabolic Health - NAD+ plays a regulatory role in insulin sensitivity and fat oxidation, making it a natural complement to GLP-1 and metabolic wellness programs. [8]

NAD+ levels naturally decline with age - research documents a drop of approximately 40-50% between youth and midlife, with further decline into older age - making therapeutic replenishment an increasingly compelling option for adults seeking to preserve vitality and longevity. [9,10]

Why NAD+ Belongs on Tru2u.health

The addition of NAD+ therapy deepens Tru2u.health's clinical offering and creates powerful synergies across the platform's existing pillars:

• Metabolic Synergy - NAD+ + GLP-1 Programs: NAD+'s role in insulin sensitivity and fat metabolism [8] makes it an ideal companion therapy for patients in GLP-1-based weight management programs.
• Performance & Recovery - NAD+ + Peptide Protocols: Combining NAD+ with peptide solutions supports cellular repair, tissue recovery, and sustained physical performance. [1,3]
• Safe, Personalized Delivery - NAD+ + Telehealth Oversight: Board-certified providers on Tru2u.health evaluate each patient individually, ensuring NAD+ therapy is administered appropriately, safely, and in alignment with the patient's broader health goals.

A Fully Integrated Digital Health Platform

www.Tru2u.health is a digital health platform dedicated to helping individuals achieve their health goals through medication-based treatment, clean supplementation, and clinically guided wellness solutions. The platform's five core pillars include:

• NAD+ Therapy - Clinically supervised NAD+ programs designed to support cellular energy, healthy aging, cognitive performance, and metabolic function.
• Peptide Solutions - Access to emerging peptide-based protocols designed to support metabolic health and performance, where clinically appropriate and compliant.
• GLP-1-Based Weight Management - Physician-guided programs utilizing GLP-1 therapies as part of a structured, medically supervised treatment plan.
• Board-Certified Telehealth Support - Ongoing clinical oversight, virtual consultations, and personalized care plans delivered through a secure digital experience.
• Clean Supplements - Science-backed, premium formulations focused on ingredient integrity and transparency.

By integrating medication-based treatment with clean supplementation and expert clinical oversight, www.Tru2u.health simplifies what has historically been a fragmented wellness journey.

Influencer-Led National Launch

The expansion is being supported by an initial wave of social media influencers across health, fitness, lifestyle, and performance categories. These partnerships are designed to deliver authentic education around responsible wellness solutions, including the science and benefits of NAD+ therapy.

This digitally native go-to-market approach positions www.Tru2u.health to scale efficiently while maintaining clinical integrity and regulatory compliance.

Built for Responsible, Scalable Growth

The www.Tru2u.health platform is structured to:

• Provide individualized treatment plans tailored to each patient's unique health goals
• Support subscription-based, recurring revenue models
• Leverage influencer-driven digital acquisition strategies
• Expand into additional therapeutic and wellness categories over time

www.Tru2u.health is now live and onboarding patients nationwide for NAD+ therapy and all platform services, subject to applicable state telehealth and prescribing regulations.

About Functional Brands Inc., Kirkman® and Tru2u.health
Functional Brands Inc. is a health and wellness company focused on acquiring and growing science-based consumer brands. With a portfolio that includes trusted names like Kirkman®, P2i by Kirkman®, Tru2u.Health™; Functional Brands is committed to providing high-quality, effective solutions that support healthier lives.

Kirkman® has been the leader in Ultratested® supplements since 1949, setting the gold standard in purity and hypoallergenic formulation. Our rigorous standards ensure that even the most sensitive communities-including those who cannot tolerate other supplements-can thrive from our formulations. With more than 70 years of clean science behind every product, Kirkman® is trusted by practitioners and patients worldwide.

Tru2u.health is a personalized health and wellness platform that connects consumers with trusted products, providers and resources tailored to their individual health journeys. Built on the conviction that no two paths to health are alike, Tru2u.health delivers guidance and solutions that are genuinely true to you.

For more information, visit www.functionalbrandsinc.com and www.kirkmangroup.com, and www.Tru2u.health

Investor Relations Contact:
FunctionalBrands@icrinc.com

Scientific References
The following peer-reviewed studies and clinical publications support the scientific claims made in this press release:
[1] Covarrubias et al., "Role of NAD+ in regulating cellular and metabolic signaling pathways," NIH/PMC
[2] Imai S. & Guarente L., "It takes two to tango: NAD+ and sirtuins in aging/longevity control," npj Aging and Mechanisms of Disease, 2016
[3] Bohr V.A., "Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage," Aging Cell, 2025
[4] Guarente L., "Sirtuins, aging and diseases," BMC Proceedings, 2012; MIT Glenn Laboratories
[5] Campbell J.M., "Supplementation with NAD+ and Its Precursors to Prevent Cognitive Decline across Disease Contexts," Nutrients, 2022 (NIH/PMC)
[6] Zhao et al., "NAD+ improves cognitive function and reduces neuroinflammation," Journal of Neuroinflammation, 2021 (NIH/PMC)
[7] Tarantini et al., "Nicotinamide mononucleotide supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses," Redox Biology, 2019
[8] Gomes et al., "Dysregulation of NAD+ Metabolism Links Mitochondrial Dysfunction to Aging and Disease," Targeting NAD+ in Metabolic Disease, NIH/PMC
[9] Massudi et al., "The Plasma NAD+ Metabolome Is Dysregulated in Normal Aging," NIH/PMC
[10] Campbell et al., PRISMA-guided systematic review of NAD supplementation, ScienceDirect, 2026

Cautionary Note Regarding Forward Looking Statements
This news release and statements of Functional Brands' management in connection with this news release or related events contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "potential," "will," "should," "could," "would," "optimistic" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control.

Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Functional Brands' Registration Statement filed with the SEC on Form S-1 on October 16, 2025 and the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2026 for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294829

FAQ

What is Tru2u.health adding to its platform on April 29, 2026 (MEHA)?

Tru2u.health added clinically supervised NAD+ therapy to its digital platform. According to the company, NAD+ joins peptide protocols, GLP-1 programs, telehealth oversight, and clean supplements for integrated, medication-based wellness care.

How does NAD+ therapy integrate with MEHA's GLP-1 weight management programs?

NAD+ is presented as complementary to GLP-1 programs by supporting insulin sensitivity and fat metabolism. According to the company, the combination aims to create metabolic synergy across Tru2u.health's physician-guided weight-management protocols.

Will Tru2u.health provide medical oversight for NAD+ therapy (MEHA)?

Yes. Board-certified providers will evaluate and oversee NAD+ therapy on Tru2u.health. According to the company, telehealth clinicians personalize treatment plans and ensure administration aligns with patient goals and state prescribing rules.

Is Tru2u.health accepting patients nationwide for NAD+ therapy under MEHA?

Tru2u.health is onboarding patients nationwide for NAD+ therapy, subject to state telehealth and prescribing regulations. According to the company, availability depends on applicable state-level telehealth rules and clinician discretion.

How is MEHA promoting the NAD+ launch for Tru2u.health?

The company is using an influencer-led national launch across health, fitness, and lifestyle channels. According to the company, influencer partnerships aim to educate consumers while scaling digital acquisition with clinical oversight.